As of 2025-12-19, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (11.63) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -235.0%.
The range of the Relative Valuation is (8.51) - (12.18) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.2x - 24.9x | 21.0x |
| Forward P/E multiples | 17.4x - 35.6x | 26.5x |
| Fair Price | (8.51) - (12.18) | (11.63) |
| Upside | -198.8% - -241.4% | -235.0% |
| Date | P/E |